Last updated on June 2017

First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer

Brief description of study

This is a First in Human study of a new single agent (MTL-CEBPA) in patients with advanced cancer of the liver. The study is in two parts: dose escalation followed by a dose expansion; both parts of the study will recruit advanced hepatocellular carcinoma patients with cirrhosis. All participants will be refractory to or ineligible for loco-regional therapy including surgery, radiofrequency tumour ablation, transarterial chemoembolisation or sorafenib. MTL-CEBPA consists of a double stranded RNA formulated into a SMARTICLES® liposomal nanoparticle and is designed to activate the CEBPA gene.

Clinical Study Identifier: NCT02716012


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Dr Han Chong Toh

National Cancer Centre
Singapore, Singapore
  Connect »

Dr Cheng Ean Chee

National University Hospital
Singapore, Singapore
  Connect »

Professor Kai-Wen Huang

National Taiwan University Hospital
Taipei, Taiwan
  Connect »

Dr yuk-Ting Ma

University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom
  Connect »

Dr Bristi Basu

Cambridge University Hospitals NHS Trust
Cambridge, United Kingdom
  Connect »

Professor Jeff Evans

The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
  Connect »

Professor Daniel Palmer

Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, United Kingdom
  Connect »

Dr Debashis Sarker

Guy's and St. Thomas' NHS Foundation Trust
London, United Kingdom
  Connect »

Professor Long R Jiao

Imperial College Healthcare NHS Trust
London, United Kingdom
  Connect »

Professor Tim Meyer

University College London Hospitals NHS Foundation Trust
London, United Kingdom
  Connect »

Professor Ruth Plummer

Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle, United Kingdom
  Connect »